2024
Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Reddy K, Paltiel A, Freedberg K, Rigotti N. Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation. JAMA Health Forum 2024, 5: e242647. PMID: 39177985, PMCID: PMC11344233, DOI: 10.1001/jamahealthforum.2024.2647.Peer-Reviewed Original ResearchConceptsPublic health benefitsCessation medicationsSmoking cessationStop smokingLife yearsLong-term abstinenceCivilian noninstitutionalized adultsTobacco cessation treatmentTobacco cessation medicationsPotential public health benefitsPopulation-level life expectancyLife expectancySmoking cessation medicationsLife expectancy gainsHealth benefitsPotential public health impactPublic health impactSmoking cessation aidTobacco cessationNoninstitutionalized adultsNoninstitutionalized populationMain OutcomesCessation treatmentCessation aidsYear of availabilityTobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study
Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D, Rigotti N, Siedner M, Wood R, Paltiel A, Freedberg K, Hyle E, Reddy K. Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study. Journal Of The International AIDS Society 2024, 27: e26315. PMID: 38924347, PMCID: PMC11197963, DOI: 10.1002/jia2.26315.Peer-Reviewed Original ResearchConceptsMortality hazard ratioSmoking cessationLife yearsNever smoking statusLife expectancyVirologically suppressed PWHSmoking statusTobacco smokeIntegrate tobacco cessation interventionsMortality riskHazard ratioTobacco cessation interventionsSmoking cessation increasesTobacco-related illnessesImpact of tobacco smokingAntiretroviral therapyMortality risk increaseProportion of deathsChronic respiratory conditionsImpact of smokingCohort of PWHVirological non-suppressionCessation interventionsVirologic suppressionHIV care
2020
Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases 2020, 73: e1927-e1935. PMID: 32730625, PMCID: PMC8492162, DOI: 10.1093/cid/ciaa1061.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHIV transmissionAge 15High-risk young menAdolescent Medicine Trials NetworkAntiretroviral therapy initiationIncremental cost-effectiveness ratioNew HIV infectionsLife expectancyYoung menCost-effectiveness ratioFrequent HIVCD4 countHIV screeningTherapy initiationHIV infectionClinical outcomesHIV incidenceClinical benefitFrequent screeningART costsHIVAge 30Trials NetworkYMSM
2019
Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector
Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, Paltiel AD, Freedberg KA, Reddy KP. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India’s public sector. PLOS ONE 2019, 14: e0218890. PMID: 31265470, PMCID: PMC6605662, DOI: 10.1371/journal.pone.0218890.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLife expectancySmear microscopyXpert MTB/RIFHIV-negative adultsPeripheral healthcare settingsMTB/RIFPrimary healthcare facilitiesSputum smear microscopyCost-effectiveness ratioCost-effectiveness analysisPresumptive tuberculosisTB diagnosisTB prevalenceTruenatMicroscopy centresXpertBudget impactRifampicin resistanceDiagnostic strategiesTuberculosisTB detectionHealthcare settingsDiagnostic sensitivityNovel molecular assayCost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis
Ouattara EN, MacLean RL, Danel C, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis. PLOS ONE 2019, 14: e0219068. PMID: 31247009, PMCID: PMC6597104, DOI: 10.1371/journal.pone.0219068.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioImmediate ARTImmediate ART initiationART initiationBudget impactLife expectancyImmediate antiretroviral therapy initiationDecrease HIV transmissionLate ART initiationModest budget impactAntiretroviral therapy initiationMedical resource useCost-effectiveness ratioCost-effectiveness analysisTherapy initiationHIV infectionHIV transmissionCôte d'IvoireART costsART efficacySTART trialCare budgetCD4CareOutcomes
2018
2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector
Lee D, Kumarasamy N, Resch S, Sivaramakrishnan G, Mayer K, Tripathy S, Paltiel A, Freedberg K, Reddy K. 2000. Rapid, Point-of-care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness and Budgetary Impact Analysis for India’s Public Sector. Open Forum Infectious Diseases 2018, 5: s582-s582. PMCID: PMC6254532, DOI: 10.1093/ofid/ofy210.1656.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioPublic healthcare facilitiesLife expectancyXpert MTB/RIFHIV-negative patientsPeripheral healthcare settingsHealthcare facilitiesBudgetary impact analysisMTB/RIFDiagnostic test costsSputum smear microscopyCost-effectiveness ratioMulti-way sensitivity analysesTB outcomesTB diagnosisPoint of careTruenatSmear microscopyXpertBudget impactTuberculosis diagnosticsDiagnostic strategiesHealthcare expendituresHealthcare settingsRifampin resistanceThe cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil
Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, Paltiel AD. The cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Journal Of The International AIDS Society 2018, 21: e25096. PMID: 29603888, PMCID: PMC5878414, DOI: 10.1002/jia2.25096.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHIV infectionTransgender womenPrEP effectivenessHigh riskMedical costsPre-exposure prophylaxis programHIV pre-exposure prophylaxisAnnual HIV incidenceUniversal ART accessPre-exposure prophylaxisHIV testing frequencyDirect medical costsHigh-risk MSMLife expectancyHIV infection riskUndiscounted life expectancyCost-effectiveness ratioYears of lifeUnited States dollarsHIV careHIV incidenceMean ageProphylaxis programART access
2017
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases 2017, 4: ofx081. PMID: 28680903, PMCID: PMC5490502, DOI: 10.1093/ofid/ofx081.Peer-Reviewed Original ResearchHIV cure strategiesCure strategiesHuman immunodeficiency virus (HIV) eradicationLifetime antiretroviral therapySustained viral eradicationElimination of HIVStandard of careLifetime costsAntiretroviral therapyViral eradicationHIV cureFatal toxicitySingle interventionVirus eradicationLife expectancyCureLower lifetime costsSingle caseSurvival
2016
Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study
Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. The Journal Of Infectious Diseases 2016, 214: 1672-1681. PMID: 27815384, PMCID: PMC5144729, DOI: 10.1093/infdis/jiw430.Peer-Reviewed Original ResearchConceptsSmoking statusSmoking cessationUS smokersLife expectancyT-cell countsHIV treatment programsAge 40 yearsYears of lifeSex-specific dataAntiretroviral therapyInitial CD4Current smokersFormer smokersHIV diseaseHIV infectionCigarette smokingMortality riskSmokersHIVSmoke cigarettesYounger ageTreatment programCessation ageSmokingCessationLaboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies
Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, Paltiel AD, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases 2016, 62: 1454-1462. PMID: 26936666, PMCID: PMC4872286, DOI: 10.1093/cid/ciw117.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioAntiretroviral therapyHuman immunodeficiency virusImmunologic failureLaboratory monitoringAIDS Complications-International modelFirst-line antiretroviral therapyBudget impactSecond-line antiretroviral therapyMean CD4 countStandard of careCost-effectiveness ratioLaboratory test costsCD4 monitoringART initiationCD4 countHIV infectionVL monitoringClinical outcomesImmunodeficiency virusCôte d'IvoireMean timeLife expectancyTherapyVL strategiesSurvival benefits of antiretroviral therapy in Brazil: a model‐based analysis
Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP. Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis. Journal Of The International AIDS Society 2016, 19: 20623. PMID: 27029828, PMCID: PMC4814587, DOI: 10.7448/ias.19.1.20623.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive patientsSurvival benefitART initiationEligible HIV-positive patientsProvision of ARTDramatic survival benefitsSubsequent ART regimensMean CD4 countLife expectancyNumber of patientsProjected life expectancyART regimensCD4 countHigher CD4HIV diseaseRegimen efficacyLife expectancy increasesEra 1PatientsTherapyNational programExpectancyCD4Regimens
2015
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 152-161. PMID: 25415289, PMCID: PMC4294967, DOI: 10.1097/qai.0000000000000426.Peer-Reviewed Original ResearchConceptsGenotype resistance testingART initiationAntiretroviral treatmentART costsGenotype testingEvandro Chagas Clinical Research InstituteResistance prevalenceFirst-line ART initiationHIV Clinical CohortHIV treatment guidelinesIncremental cost-effectiveness ratioBaseline patient characteristicsEffective antiretroviral treatmentART-naive individualsLife expectancyClinical Research InstituteCost-effectiveness ratioImmune recoveryCD4 countViral suppressionHIV diseasePatient characteristicsTreatment guidelinesMean agePrimary resistance
2014
The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis
Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, Walensky RP. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLOS Medicine 2014, 11: e1001725. PMID: 25225800, PMCID: PMC4165752, DOI: 10.1371/journal.pmed.1001725.Peer-Reviewed Original ResearchConceptsCare CD4 testIncremental cost-effectiveness ratioCare CD4 testingPOC CD4CD4 testCD4 testingResource-limited settingsHIV diagnosisHIV testingClinical outcomesAntiretroviral therapy (ART) eligibilityPerson lifetime costsLife expectancyLifetime costsCost-effectiveness ratioResource limited settingsCost-effectiveness analysisSensitivity/specificityImmunological stagingLow sensitivity/specificityCost-effective thresholdLaboratory-based testsSurvivalEditors' SummaryOutcomesMobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness
Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R, Walensky RP, Losina E, Bekker LG, Freedberg KA. Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. PLOS ONE 2014, 9: e85197. PMID: 24465503, PMCID: PMC3898963, DOI: 10.1371/journal.pone.0085197.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioFacility-based testingHIV screeningHIV diagnosisFacility-based HIV testingFrequency of HIVUndiagnosed HIV prevalenceEarly HIV diagnosisLife expectancyMobile screening unitCost-effectiveness ratioResource-limited settingsCD4 countUndiagnosed HIVHIV testingHIV prevalenceCape TownClinical impactPopulation life expectancyMedical costsHIVScreening unitIntervention costsDiagnosisMedical facilities
2013
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis And Cartilage 2013, 21: 655-667. PMID: 23380251, PMCID: PMC3670115, DOI: 10.1016/j.joca.2013.01.016.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsTotal knee replacementPain reliefMajor toxicityRevision total knee replacementCare sequenceConservative pain managementGuideline-concordant careKnee OA treatmentQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioCorticosteroid injectionKnee OAKnee osteoarthritisPain managementOsteoarthritis drugsKnee replacementDMOADsOA treatmentLife yearsProgressionLife expectancyRelief
2012
The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial
Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. Drug And Alcohol Dependence 2012, 128: 90-97. PMID: 22971593, PMCID: PMC3546145, DOI: 10.1016/j.drugalcdep.2012.08.009.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsSubstance abuse treatment programsNational HIV/AIDS StrategyCost-effectiveness ratioCommunity-based substance abuse treatment programsUndiagnosed HIV prevalenceRisk reduction counselingRapid HIV testingTreatment programHIV testingHIV prevalenceSite rapid testingSite rapid HIV testingHIV risk reduction counselingHIV/AIDS StrategyIncremental cost-effectiveness ratioHIV testing strategiesLife expectancyHIV testing offerPrior testing historyReceipt of resultsSubstance abuse treatmentRapid testingHIV screeningPatient demographicsThe Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clinical Infectious Diseases 2012, 54: 1504-1513. PMID: 22474224, PMCID: PMC3334365, DOI: 10.1093/cid/cis225.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSouth African womenHIV infectionRecent trialsHIV riskLife expectancyHuman immunodeficiency virus (HIV) infectionAfrican womenIncremental cost-effectiveness ratioImmunodeficiency virus infectionAge-adjusted incidenceShort-term efficacyHIV infection incidenceHIV natural historyCost-effectiveness ratioPopulation-level transmissionPrEP efficacyHIV acquisitionLong-term impactPatient outcomesPopulation demographic characteristicsVirus infectionClinical cohortInfection incidenceCost savingsNewer drugs and earlier treatment
Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment. AIDS 2012, 26: 45-56. PMID: 22008655, PMCID: PMC3237010, DOI: 10.1097/qad.0b013e32834dce6e.Peer-Reviewed Original ResearchConceptsCD4 cell countAntiretroviral therapyHIV RNACD4 cellsHIV diseaseCells/Life expectancyCell countMean CD4 cell countMean age 38 yearsAge 38 yearsMedical resource utilizationLifetime costsUndiscounted life expectancyCost of careAIDS Complications (CEPAC) modelART initiationHIV CostRegimen costsAntiretroviral drugsART costsEarly treatmentCopies/High-income countriesEfficacious drugs
2011
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2010
Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, Investigators F. Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. PLOS Medicine 2010, 7: e1000382. PMID: 21209794, PMCID: PMC3014084, DOI: 10.1371/journal.pmed.1000382.Peer-Reviewed Original ResearchConceptsHIV treatment guidelinesART initiationTreatment guidelinesStage III/IV diseaseLong-term survival advantageEarly antiretroviral therapy initiationAntiretroviral therapy initiationLife expectancySouth African HIVResource limited settingsProjected life expectancyResource-limited settingsGreater life expectancyART regimensTherapy initiationAfrican HIVGuideline componentsSurvival advantageWHO recommendationsTenofovirRegimensStavudineSurvivalGuidelinesInitiation